In a new study, Chinese researchers have discovered the previously unrecognized role of alternative splicing of the DOC2A ...
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...
The modulation of RNA splicing by small molecules has emerged as a promising strategy for treating pathogenic infections, human genetic diseases, and cancer; however, the principles by which splicing ...
Pleasanton, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTCQB) PK: PKBO), announced that it was awarded US Patent No. 11,691,982 B2 entitled “Thailanstatin ...
The MarketWatch News Department was not involved in the creation of this content. -- Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund ...
New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.
Pleasanton, CA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing and commercializing ...
SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in ...
SpliceBio has dosed the first patient in the Part B dose-expansion portion of its phase 1/2 ASTRA clinical trial ( NCT06942572) evaluating SB-007 for the treatment of Stargardt disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback